$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000161883522000057 Filed on March 10, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$3.570M	$8.244M	$170.0K
YoY Change	2000.0%	1748.43%
Cost Of Revenue	$1.755M	$4.055M	$250.0K
YoY Change	602.0%	766.45%
Gross Profit	$1.815M	$4.189M	-$80.00K
YoY Change	-2368.75%	-19140.91%
Gross Profit Margin	50.84%	50.81%	-47.06%
Selling, General & Admin	$30.57M	$137.9M	$29.92M
YoY Change	2.19%	59.28%	216.95%
% of Gross Profit	1684.52%	3291.02%
Research & Development	$8.659M	$33.13M	$5.950M
YoY Change	45.53%	94.3%	73.47%
% of Gross Profit	477.08%	790.86%
Depreciation & Amortization	$285.0K	$1.023M	$120.0K
YoY Change	137.5%	241.0%	100.0%
% of Gross Profit	15.7%	24.42%
Operating Expenses	$39.23M	$171.0M	$35.87M
YoY Change	9.38%	64.3%	178.67%
Operating Profit	-$37.42M	-$166.8M	-$35.95M
YoY Change	4.08%	60.97%
Interest Expense	-$12.92M	$2.665M	-$3.670M
YoY Change	252.02%	29.31%	-3158.33%
% of Operating Profit
Other Income/Expense, Net	-$1.211M	-$38.37M	-$1.070M
YoY Change	13.18%	-0.79%	-790.32%
Pretax Income	-$51.55M	-$205.2M	-$40.60M
YoY Change	26.97%	44.18%	219.18%
Income Tax	$6.000K	$17.00K	$0.00
% Of Pretax Income
Net Earnings	-$51.55M	-$205.2M	-$40.60M
YoY Change	26.98%	44.19%	219.26%
Net Earnings / Revenue	-1444.09%	-2488.99%	-23882.35%
Basic Earnings Per Share		-$1.58
Diluted Earnings Per Share	-$4.786M	-$1.58	-$499.3K
COMMON SHARES
Basic Shares Outstanding	163.1M shares	130.9M shares	81.28M shares
Diluted Shares Outstanding		130.9M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.732M	$7.732M	$48.90M
YoY Change	-84.19%	-84.19%	105.46%
Cash & Equivalents	$7.732M	$7.732M	$48.89M
Short-Term Investments			$0.00
Other Short-Term Assets	$8.285M	$8.285M	$40.40M
YoY Change	-79.49%	-79.49%	2026.32%
Inventory	$7.915M	$7.674M	$7.162M
Prepaid Expenses
Receivables	$6.449M	$6.449M	$1.067M
Other Receivables	$0.00	$0.00	$200.0K
Total Short-Term Assets	$30.14M	$30.14M	$97.73M
YoY Change	-69.16%	-69.15%	269.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.774M	$11.17M	$4.334M
YoY Change	33.23%	-0.28%	1000.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.203M	$1.203M	$1.048M
YoY Change	14.79%	20.3%	-20.61%
Total Long-Term Assets	$12.37M	$12.37M	$12.24M
YoY Change	1.09%	0.59%	553.04%
TOTAL ASSETS
Total Short-Term Assets	$30.14M	$30.14M	$97.73M
Total Long-Term Assets	$12.37M	$12.37M	$12.24M
Total Assets	$42.51M	$42.51M	$110.0M
YoY Change	-61.34%	-61.35%	288.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.32M	$10.32M	$10.64M
YoY Change	-3.05%	-2.68%	77.11%
Accrued Expenses	$8.370M	$15.36M	$4.476M
YoY Change	87.0%	15.45%	60.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$52.40M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$108.9M	$108.9M
YoY Change		107.84%
Total Short-Term Liabilities	$137.7M	$137.7M	$77.28M
YoY Change	78.13%	78.09%	510.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$25.20M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$4.424M	$4.424M	$6.100M
YoY Change	-27.48%	-27.48%
Total Long-Term Liabilities	$4.424M	$4.424M	$31.30M
YoY Change	-85.87%	-85.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$137.7M	$137.7M	$77.28M
Total Long-Term Liabilities	$4.424M	$4.424M	$31.30M
Total Liabilities	$142.1M	$142.1M	$108.6M
YoY Change	30.81%	30.84%	758.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$860.7M		-$655.5M
YoY Change	31.3%		27.73%
Common Stock	$751.3M		$656.8M
YoY Change	14.38%		24.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$104.3M	-$99.58M	$1.347M
YoY Change
Total Liabilities & Shareholders Equity	$42.51M	$42.51M	$110.0M
YoY Change	-61.34%	-61.35%	288.65%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$51.55M	-$205.2M	-$40.60M
YoY Change	26.98%	44.19%	219.26%
Depreciation, Depletion And Amortization	$285.0K	$1.023M	$120.0K
YoY Change	137.5%	241.0%	100.0%
Cash From Operating Activities	-$21.27M	-$146.7M	-$39.08M
YoY Change	-45.59%	39.91%	190.56%
INVESTING ACTIVITIES
Capital Expenditures	-$53.00K	$2.939M	-$1.420M
YoY Change	-96.27%	30.39%	914.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$250.0K	$0.00
YoY Change		-97.05%	-100.0%
Cash From Investing Activities	-$53.00K	-$2.689M	-$1.420M
YoY Change	-96.27%	-143.17%	-69.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	9.866M	$90.69M	24.92M
YoY Change	-60.41%	-41.19%	1032.73%
NET CHANGE
Cash From Operating Activities	-21.27M	-$146.7M	-39.08M
Cash From Investing Activities	-53.00K	-$2.689M	-1.420M
Cash From Financing Activities	9.866M	$90.69M	24.92M
Net Change In Cash	-11.45M	-$58.66M	-15.58M
YoY Change	-26.5%	-205.46%	-1.89%
FREE CASH FLOW
Cash From Operating Activities	-$21.27M	-$146.7M	-$39.08M
Capital Expenditures	-$53.00K	$2.939M	-$1.420M
Free Cash Flow	-$21.21M	-$149.6M	-$37.66M
YoY Change	-43.67%	39.71%	182.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36754
CY2021	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	12400 High Bluff Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	550-1900
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	172915009	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	167783009	shares
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.44
CY2021Q4	evfm	Debt Instrument Convertible Conversion Price Percentage Of Lowest Stock Price DebtInstrumentConvertibleConversionPricePercentageOfLowestStockPrice	1.15
CY2021Q4	evfm	Debt Instrument Convertible Conversion Price Percentage Of Lowest Stock Price DebtInstrumentConvertibleConversionPricePercentageOfLowestStockPrice	1.15
CY2021Q4	evfm	Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities	50000000	USD
CY2021	evfm	Debt Instrument Restrictive Covenants Cumulative Net Sales Requirement DebtInstrumentRestrictiveCovenantsCumulativeNetSalesRequirement	100000000	USD
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, CA
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7732000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48892000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5056000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	22559000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6449000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1067000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7674000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7162000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30140000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	97730000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5774000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5395000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6856000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1203000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1048000	USD
CY2021Q4	us-gaap	Assets Assets	42512000	USD
CY2020Q4	us-gaap	Assets Assets	109968000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10316000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10641000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4653000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6514000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2332000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2290000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2864000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	953000	USD
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	137663000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77283000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4424000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6030000	USD
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	25211000	USD
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	97000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	142087000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	108621000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162500425	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	162500425	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81351533	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81351533	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	751260000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	656827000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5089000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860680000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-655488000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42512000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109968000	USD
CY2021	us-gaap	Revenues Revenues	8244000	USD
CY2020	us-gaap	Revenues Revenues	446000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4055000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	468000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33129000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17050000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	113152000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	56467000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24709000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30085000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	175045000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	104070000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-166801000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-103624000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	169000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4732000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2082000	USD
CY2021	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	USD
CY2020	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64049000	USD
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-33657000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	27281000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38374000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38681000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-205175000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142305000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-205192000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2021	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	1047000	USD
CY2020	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-206239000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-206239000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142309000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142309000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.12
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.12
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130908794	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130908794	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67157278	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67157278	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-205192000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	5089000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-200103000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142309000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2020	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	360000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2869000	USD
CY2020	evfm	Short Swing Profit Disgorgement ShortSwingProfitDisgorgement	187000	USD
CY2020	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	11015000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12697000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2021	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	297000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5662000	USD
CY2021	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	1047000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	327000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	5089000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8898000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-205192000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-205192000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-205192000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2021	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
CY2020	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	64049000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	33657000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27281000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8898000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	12697000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1023000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	302000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1404000	USD
CY2020	us-gaap	Lease Cost LeaseCost	879000	USD
CY2021	us-gaap	Interest Expense InterestExpense	2665000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2061000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	300000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5382000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1067000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6010000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13882000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17356000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4126000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5471000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2729000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1861000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2844000	USD
CY2021	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	1507000	USD
CY2020	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	493000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-146667000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104829000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2939000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2254000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8233000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2689000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6229000	USD
CY2021	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	81534000	USD
CY2020	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	103738000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	159000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
CY2021	evfm	Proceeds From Issuance Of Common Stock Net Of Commissions ProceedsFromIssuanceOfCommonStockNetOfCommissions	0	USD
CY2020	evfm	Proceeds From Issuance Of Common Stock Net Of Commissions ProceedsFromIssuanceOfCommonStockNetOfCommissions	3781000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	297000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	447000	USD
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	10000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	USD
CY2021	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	0	USD
CY2020	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	187000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	970000	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1060000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	327000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2869000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90693000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154226000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-58663000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55626000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13588000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1389000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	11000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7618000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	476000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	823000	USD
CY2021	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	0	USD
CY2020	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	11015000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1032000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021Q4	evfm	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	9600000	USD
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	81500000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7700000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	4700000	USD
CY2021Q4	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-107500000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860700000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use (ROU) assets and lease liabilities; the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued; </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the useful lives of property and equipment; the recoverability of long-lived assets; clinical trial accruals; the assumptions used in estimating the fair value of stock-based compensation expense; and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i100cc6361d37408a94f28a13d0f92675_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i100cc6361d37408a94f28a13d0f92675_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i100cc6361d37408a94f28a13d0f92675_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i100cc6361d37408a94f28a13d0f92675_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i100cc6361d37408a94f28a13d0f92675_163" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of December 31, 2021, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, who receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the years ended December 31, 2021, and 2020, the Company’s three largest customers combined made up approximately 75% and 92% of its gross product sales, respectively. As of December 31, 2021 and 2020, the Company's three largest customers combined made up 75% and 95%, respectively, of its trade accounts receivable balance.</span></div>
CY2020Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7732000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48892000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5056000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	22559000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13588000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6900000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5400000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6800000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8300000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1712000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	105116667	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19646572	shares
CY2020Q4	evfm	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	1000000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	574000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	332000	USD
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.44
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4162000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5629000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2668000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	7915000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7162000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2021Q4	evfm	Debt Instrument Convertible Number Of Shares Issuable If Converted DebtInstrumentConvertibleNumberOfSharesIssuableIfConverted	11484032	shares
CY2021Q4	evfm	Debt Instrument Convertible Conversion Price Percentage Of Lowest Stock Price DebtInstrumentConvertibleConversionPricePercentageOfLowestStockPrice	1.15
CY2021Q4	evfm	Debt Instrument Convertible Conversion Price Percentage Of Lowest Stock Price DebtInstrumentConvertibleConversionPricePercentageOfLowestStockPrice	1.15
CY2021Q4	evfm	Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities	50000000	USD
CY2021	evfm	Debt Instrument Restrictive Covenants Cumulative Net Sales Requirement DebtInstrumentRestrictiveCovenantsCumulativeNetSalesRequirement	100000000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.050
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7948000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5485000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2174000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1151000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5774000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2021	us-gaap	Depreciation Nonproduction DepreciationNonproduction	1000000	USD
CY2020	us-gaap	Depreciation Nonproduction DepreciationNonproduction	300000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	241000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent		USD
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	109000	USD
CY2020Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	214000	USD
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	53000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	34000	USD
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	1203000	USD
CY2020Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	1048000	USD
CY2021Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	5294000	USD
CY2020Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	1417000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1997000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	564000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	550000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1631000	USD
CY2021Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	201000	USD
CY2020Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	498000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	328000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	366000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2021	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	72	vehicle
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11176000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	70233000	USD
CY2021Q4	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000	USD
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2338000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1606000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y6M29D
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y5M4D
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2480000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2163000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2192000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1502000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8337000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1581000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6756000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2426000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1185000	USD
CY2021	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	3000000	USD
CY2020	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	3700000	USD
CY2021Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2019Q2	evfm	Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned	1
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	67767107	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.54
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	67767107	shares
CY2021	evfm	Convertible Preferred Stock Discount Accretion Period ConvertiblePreferredStockDiscountAccretionPeriod	P4Y
CY2021	evfm	Convertible Preferred Stock Value Issued Net Of Offering Expenses ConvertiblePreferredStockValueIssuedNetOfOfferingExpenses	9600000	USD
CY2021	evfm	Convertible Preferred Stock Discount On Shares Issued During The Period ConvertiblePreferredStockDiscountOnSharesIssuedDuringThePeriod	500000	USD
CY2021	evfm	Temporary Equity Deemed Dividend Return Of Capital TemporaryEquityDeemedDividendReturnOfCapital	800000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	67767107	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	83721748	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8898000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12697000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8935801	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.08
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	338000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3208525	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.77
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1519264	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10625062	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.34
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10625062	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.34
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7384269	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.26
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M4D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.18
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.20
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.15
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.51
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.011
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.827
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.007
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.030
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	800000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142305000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-205175000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-142305000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-205175000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0117
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0226
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0048
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0159
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0070
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0076
CY2021	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	0
CY2020	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	-0.0948
CY2021	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.0344
CY2020	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.0404
CY2021	evfm	Effective Income Tax Rate Reconciliation Tax Regulation Adjustment Percent EffectiveIncomeTaxRateReconciliationTaxRegulationAdjustmentPercent	0
CY2020	evfm	Effective Income Tax Rate Reconciliation Tax Regulation Adjustment Percent EffectiveIncomeTaxRateReconciliationTaxRegulationAdjustmentPercent	-0.0749
CY2021	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.0030
CY2020	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.0003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0068
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0045
CY2021	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	-0.0050
CY2020	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	0.0068
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1743
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0914
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	423000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	112891000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	78124000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	538000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5233000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4059000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3513000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3840000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2726000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3230000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124786000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	89791000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1218000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1621000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	101000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	457000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	123467000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	87713000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1465000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2413000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	813000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1177000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	401000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	229000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2679000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1465000	USD

Files In Submission

Name	View Source	Status
0001618835-22-000057-index-headers.html	Edgar Link	pending
0001618835-22-000057-index.html	Edgar Link	pending
0001618835-22-000057.txt	Edgar Link	pending
0001618835-22-000057-xbrl.zip	Edgar Link	pending
delawarestamp.jpg	Edgar Link	pending
evfm-12312021ex31110xk.htm	Edgar Link	pending
evfm-12312021ex31210xk.htm	Edgar Link	pending
evfm-12312021ex32110xk.htm	Edgar Link	pending
evfm-20211231.htm	Edgar Link	pending
evfm-20211231.xsd	Edgar Link	pending
evfm-20211231_cal.xml	Edgar Link	unprocessable
evfm-20211231_def.xml	Edgar Link	unprocessable
evfm-20211231_g1.jpg	Edgar Link	pending
evfm-20211231_g10.jpg	Edgar Link	pending
evfm-20211231_g11.jpg	Edgar Link	pending
evfm-20211231_g12.jpg	Edgar Link	pending
evfm-20211231_g13.jpg	Edgar Link	pending
evfm-20211231_g14.jpg	Edgar Link	pending
evfm-20211231_g15.jpg	Edgar Link	pending
evfm-20211231_g16.jpg	Edgar Link	pending
evfm-20211231_g17.jpg	Edgar Link	pending
evfm-20211231_g18.jpg	Edgar Link	pending
evfm-20211231_g19.jpg	Edgar Link	pending
evfm-20211231_g2.jpg	Edgar Link	pending
evfm-20211231_g20.jpg	Edgar Link	pending
evfm-20211231_g21.jpg	Edgar Link	pending
evfm-20211231_g22.jpg	Edgar Link	pending
evfm-20211231_g23.jpg	Edgar Link	pending
evfm-20211231_g3.jpg	Edgar Link	pending
evfm-20211231_g4.jpg	Edgar Link	pending
evfm-20211231_g5.jpg	Edgar Link	pending
R13.htm	Edgar Link	pending
evfm-20211231_g6.jpg	Edgar Link	pending
evfm-20211231_g7.jpg	Edgar Link	pending
evfm-20211231_g8.jpg	Edgar Link	pending
evfm-20211231_g9.jpg	Edgar Link	pending
evfm-20211231_htm.xml	Edgar Link	completed
evfm-20211231_lab.xml	Edgar Link	unprocessable
evfm-20211231_pre.xml	Edgar Link	unprocessable
exhibit1036_non-employeedi.htm	Edgar Link	pending
exhibit1063_non-employeedi.htm	Edgar Link	pending
exhibit211.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
exhibit31.htm	Edgar Link	pending
exhibit422.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2021 Q4 Form 10-K Financial Statement

#000161883522000057 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2021 Q4 Form 10-K Financial Statement

#000161883522000057 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm